Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT113 therapeutic HPV vaccine trial in HPV16-positive squamous cell carcinoma
ISRCTN51789191Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2017
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label trial of BNT113 in Human papillomavirus-positive squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC) and 3 more (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Determination of suitable dose of BNT113 and Disease control rate. Started May 2017; status: completed.
02
Drugs
BNT113
03
Conditions
Human papillomavirus-positive squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)Ano-genital Carcinomapenile cancer
Beyond the preview
Go deeper on ISRCTN51789191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51789191.